To directly compare clinical outcomes between matched related donors (MRD) and mismatched unrelated donors (MMUD) in the posttransplant cyclophosphamide era.
Approach:
Study Design: A retrospective cohort study including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome who underwent their first allogeneic MRD or MMUD peripheral blood HCT.
Statistical Analysis: Utilized inverse probability of treatment weighting (IPTW) with overlap weights to balance baseline characteristics and performed bootstrapped resampling for stability of estimates.
Key Findings:
Emerging evidence suggests that MRDs may deliver a weaker graft-vs-leukemia effect compared to MUDs or haploidentical donors.
Donor age has minimal influence on survival and relapse in the posttransplant cyclophosphamide era.
The study aims to assess if MMUD grafts exhibit a stronger graft-vs-leukemia effect than MRDs.
Interpretation:
Limitations:
Contemporary comparisons of MRD and MMUD transplants are sparse and often limited by design.
The study's retrospective nature may introduce biases.
by Rohtesh S. Mehta, Yosra M. Aljawai, Partow Kebriaei, Warren Fingrut, Portia Smallbone, Betul Oran, Amanda Olson, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall
